Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a price target of $20.00. The company’s shares ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) – Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued ...

Lenoir-Rhyne University has announced that Sean Weddell is resigning from his position as Head Men’s and Women’s Swimming Coach. Weddell recently finished his first season which culminated with the ...

HICKORY, NC – Lenoir-Rhyne University has announced that Sean Weddell is resigning from his position as Head Men's and Women's Swimming Coach. Weddell recently finished his first season which ...

Award-winning distillery Gyre & Gimble has announced the launch of Curious Whiskies, an exclusive collection of single cask bottlings and an Islay peated blend, to celebrate the very best of Scotch ...